Fatty liver disease (MASLD/MASH) trials in Kazakhstan

3 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

• Phase 3Taking people
  LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

  Where

  Almaty

  Age

  18 years and over

  People

  1,800 worldwide

  Run by

  Boehringer Ingelheim

  See details and how to joinNCT06632444 · EU 2024-513739-25-00
• Phase 3Taking people
  LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

  Where

  Almaty

  Age

  18 years and over

  People

  1,590 worldwide

  Run by

  Boehringer Ingelheim

  See details and how to joinNCT06632457 · EU 2024-513741-36-00
• No phaseTaking people
  Clinical Profile of Patients With MASLD in Kazakhstan and Clinical Effectiveness of Ursosan in Almaty

  Where

  Aktau, Aktobe, Almaty, Astana, Shymkent

  Age

  18 years to 65 years

  People

  420

  Run by

  Kazakh Association of Internal Medicine Specialists

  See details and how to joinNCT07889999